ALEBUND-B(09637): Fully exercising the over-allotment option, stabilizing the price action, and the stabilization period ends.

date
16:33 24/07/2026
avatar
GMT Eight
Lepon Pharmaceutical-B (09637) announced that the joint representative (on behalf of itself and representing international underwriters) has fully exercised the oversubscription rights as stated in the prospectus on July 24, 2026 (Friday). This involves a total of 8.5133 million H shares, accounting for approximately 15% of the total number of shares available for subscription under the global offering before the exercise of oversubscription rights. The oversubscribed shares will be issued and distributed by the company at a price of HK$22.60 per H share. The oversubscribed shares will be used to supplement the oversubscription allocation of the international offering.
ALEBUND-B (09637) announced that the joint representatives (representing both itself and the international underwriters) have fully exercised the oversubscription rights as described in the prospectus on July 24, 2026 (Friday), involving a total of 8.5133 million H shares, accounting for approximately 15% of the total number of shares available for subscription under the global offering before the exercise of oversubscription rights. The oversubscribed shares will be issued and distributed by the company at a price of HK$22.60 per H share. The oversubscribed shares will be used to supplement the oversubscription allocation for the international offering. In accordance with Rule 9(2) of the Securities and Futures (Stabilization Price) Rules (Chapter 571W of the Laws of Hong Kong), the company announced that the stabilization period for the global offering has ended on July 24, 2026 (Friday) (i.e. the 30th day after the deadline for submitting the Hong Kong public offering application).